Despite being on the market for less than three years, GLP-1 medicines, Mounjaro and Zepbound, became key top-line drivers ...

Novo Nordisk shares have come under pressure amid weight-loss drug competition, while UK health officials have launched a ...

Eli Lilly poised for 30-50% growth in 12 months with a strong value and growth nexus. Click here to read more on LLY stock.

Novo Nordisk is seen as having fallen behind in the race for new obesity drugs. It argues it is playing the long game.

We came across a bullish thesis on Novo Nordisk A/S on Kontra Investments’ Substack by Kontra. In this article, we will ...